Share

Diurnal Group Plc - news published 25 - readings 1.215

BACK
Diurnal Group plc

Diurnal Group plc

Distribution agreement signed with ExCEEd Orphan for Central and Eastern Europe

Agreement extends the Company's commercial footprint to over two-thirds of the European Economic Area population Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has signed a distribution agreement with ExCEEd Orphan, a company providing full business solutions for the treatme ...

Continue reading
14.10.2021
Diurnal Group plc

Diurnal Group plc

Diurnal receives Special Protocol Assessment Agreement for Chronocort® from the FDA

Pivotal Phase 3 trial expected to commence in the US in H2 2021 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces that the US Food and Drug Administration (FDA) has agreed a Special Protocol Assessment (SPA) for Chronocort® (modified-release hydrocortisone) for the design, endpo ...

Continue reading
12.07.2021
Diurnal Group plc

Diurnal Group plc

Chronocort® Phase 3 and Safety Extension Study results published in JCEM

Posted on Tuesday, 02/Feb/2021 Posted by michelle Peer-reviewed data from largest ever completed interventional clinical trial in CAH Authors conclude that Chronocort ® provides a well-tolerated and practical twice-daily treatment regimen for CAH Data also forms part of EMA and MHRA submissions with anticipated positive regulatory opinion in Q1 2021 Diurnal Group plc (AIM: DN ...

Continue reading
02.02.2021